ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions
View by Date

Tuesday, November 7, 2017

9:00AM-11:00AM
Abstract Number: 1937
Abaloparatide, an Osteoanabolic PTHrP Analog, Increased Bone Mineral Density in Rabbits with Glucocorticoid Induced Osteopenia
Biology and Pathology of Bone and Joint Poster II
9:00AM-11:00AM
Abstract Number: 2705
Aberrant Expression and Function of Human Circulating T Follicular Helper Cells and Its Subsets in IgG4 Related Disease
T Cell Biology and Targets in Autoimmune Disease Poster II
9:00AM-11:00AM
Abstract Number: 2421
Aberrant Expression of CaMK4 in CD4 Positive T Cells Predicts Poor Response to Treatment in Patients with Active Rheumatoid Arthritis
Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster III
9:00AM-11:00AM
Abstract Number: 2652
Abnormal Expression of Long Noncoding RNA Lncrna-CMPK2 Facilitates Neutrophils Interferon Production By TLR7/8 Agonist Stimulation in SLE
Systemic Lupus Erythematosus – Human Etiology and Pathogenesis Poster II
9:00AM-11:00AM
Abstract Number: 2549
Achievement of Minimal Disease Activity Is Associated with Improvements in Health-Related Quality of Life and Productivity in Psoriatic Arthritis Patients
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities
9:00AM-11:00AM
Abstract Number: 2431
Acquisition of Protective Alleles in Women with Rheumatoid Arthritis through Microchimerism
Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster III
9:00AM-11:00AM
Abstract Number: 2283
Adalimumab Therapy in Juvenile Idiopathic Arthritis:   Addition of Lidocaine for Prevention of Injection Site Pain or Not? That Is the Question.   a Comparison Study
Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis
9:00AM-11:00AM
Abstract Number: 2723
Adalimumab Therapy Optimization in Refractory Uveitis Due to Behçet’s Disease after Achieving Remission. interventional Versus Control Group
Vasculitis Poster III: Other Vasculitis Syndromes
9:00AM-11:00AM
Abstract Number: 2135
ADAM-17 Is Expressed in the Inflammatory Myopathy, and Is Involved with Interstitial Lung Disease
Muscle Biology, Myositis and Myopathies Poster
9:00AM-11:00AM
Abstract Number: 2043
Adherence to American College of Rheumatology Guidelines for Prevention of Glucocorticoid-Induced Osteoporosis in Patients with Polymyalgia Rheumatica
Measures and Measurement of Healthcare Quality Poster II
9:00AM-11:00AM
Abstract Number: 1943
Adipocytokines in an Osteoarthritis Mouse Model
Biology and Pathology of Bone and Joint Poster II
9:00AM-11:00AM
Abstract Number: 2333
Adjudication of Infections from the Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (PHARMACHILD) Treated with Biologic Agents and/or Methotrexate with a Focus on Opportunistic Infections
Pediatric Rheumatology – Pathogenesis and Genetics Poster
9:00AM-11:00AM
Abstract Number: 2543
Agreement between Paper and Pencil VAS at the Clinic and Electronic VAS at Home in Psoriatic Arthritis and Its Impact on Minimal Disease Activity
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities
9:00AM-11:00AM
Abstract Number: 2087
Allelic Variants of ABCG2 and Gout Risk
Metabolic and Crystal Arthropathies Poster II
9:00AM-11:00AM
Abstract Number: 2059
Allopurinol Dose-Titration Patterns Relative to Serum Uric Acid Levels in Gout Patients: US Electronic Health Record Data
Metabolic and Crystal Arthropathies Poster II
  • «Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 65
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology